Blogs | MedChemExpress

Geptanolimab (CBT-501) is a Anti-PD-1 Monoclonal Antibody for Solid Tumor Research

Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
Mogamulizumab is a Defucosylated Anti-CCR4 Monoclonal Antibody

Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
U7D-1 is a Selective USP7 PROTAC Degrader For Leukemia Research

U7D-1 is a selective USP7 PROTAC degrader. U7D-1 induces apoptosis in Jeko-1 cells and shows anticancer activity.
Abexinostat is an Orally Available Pan-HDAC Inhibitor

Abexinostat, a potent and broad-spectrum inhibitor of histone deacetylases, can be used for the research of cancer.
ABT-510 is an Anti-Angiogenic Thrombospondin Peptide

ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
Golcadomide is an Orally Active CRBN E3 Ligase Modulator (CELMoD)

Golcadomide is a potent and orally active CRBN E3 ligase modulator with immunomodulating and antineoplastic activities.
Parsatuzumab (RG 7414) is a Humanized mAb, Binding to EGFL7

Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
Tirabrutinib is a Selective BTK Inhibitor

Tirabrutinib is a selective and novel inhibitor of BTK, Tirabrutinib prevents B-cell receptor signaling and impeding B-cell development.
Repotrectinib is a potent ROS1 and TRK Inhibitor

Repotrectinib is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib has anti-cancer activity.
Apitolisib is an Orally Active Class I PI3K and mTORC1/2 Inhibitor

Apitolisib is a potent Class I PI3 kinase and mTORC1/2 inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, respectively.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (59)